[Asia Economy Reporter Ji Yeon-jin] Eutilex announced on the 17th that it has received approval from the Ministry of Food and Drug Safety for the Phase 1 and 2 clinical trial plans of the immuno-oncology drug EU101.
The Phase 1 trial will evaluate the safety, efficacy, and pharmacokinetics of EU101, an anti-CD137 (4-1BB) agonist monoclonal antibody, in patients with advanced solid tumors, and will determine the maximum tolerated dose and the recommended dose for Phase 2. The Phase 2 trial will assess the antitumor effects of EU101 in colorectal and non-small cell lung cancers.
The company stated, "EU101 activates and proliferates killer T cells of the immune system that attack cancer in patients with advanced solid tumors, which is expected to minimize treatment side effects, reduce and control tumor size, extend progression-free survival, prolong overall survival, and improve quality of life."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
